400 million patients are affected by retinal diseases Their number is to double over the next 40 years Over 50% of cases remain undiagnosed 92 firms are developing new retinal therapies

Why do we advance retinal imaging?

Diagnose earlier

Retinal diseases affect 400 million patients worldwide. Moreover 1 billion people suffer from other health conditions that impact the back of the eye, such as hypertension and diabetes. Unfortunately, early retinal symptoms are hard to detect and, as a result, massive numbers of cases remain undiagnosed.

Treat better

While new therapies are reaching the market, doctors have the key role of choosing the best treatment option for each individual patient. Their task is difficult because it takes months to evaluate how a patient responds to a therapy. As a consequence, millions of people are being treated with drugs that are not optimal for them.

Improve health

Imagine Eyes® addresses these major health issues with advanced biophotonics technology. We create new retinal imaging devices in order to help preserve sight, prevent handicap and save lives.

Leading technology pioneer

Imagine Eyes has introduced adaptive optics imaging in medicine. With our rtx1™ product, doctors can see details as small as single cells in patients’ retinas. They can  track microscopic retinal lesions that were previously invisible.

Doctors who adopted the rtx1 have published more than 200 peer-reviewed articles. Their investigations have revealed new insights into not only retinal diseases, but also arterial hypertension, vascular inflammation and diabetes.

Imagine Eyes is now deploying the rtx1 through an international network of distributors. Meanwhile, our engineers keep developing tomorrow’s retinal imaging technology.

Quality inseparable from innovation

Imagine Eyes’ approach of quality starts with listening to customers and results in medical devices that match previously unmet needs. Our R&D projects have been awarded by the most selective research funding programs, such as the European Commission’s FP7 and Horizon 2020 programs. To see an example, click here and take a look at the MERLIN project web page.

From the beginning to the end of the innovation cycle, we make sure to comply with the most recent regulations and international standards. Imagine Eyes is ISO13485-certified, and our medical products have received regulatory clearance in the European Union and Japan. If you’d like to receive a copy of our certificates, please contact our customer support.


Imagine Eyes unites specialists in biophotonics imaging, software engineering, as well as ophthalmic business. Beyond technical expertise, we also value the soft skills that enable our team to collaborate with leading clinicians, scientists and distributors.

Inside the company as well as in partnerships, teamwork is driven by shared ambitions: develop international business and make a positive impact on global health.

Management and board of directors

Nicolas Chateau, PhD, has built his career on bringing innovative ophthalmic products to market. Since he cofounded Imagine Eyes in 2003, he has established partnerships with scientific and clinical centers, secured several millions euros in grant funding, and driven the team’s effort to market breakthrough medical imaging devices. Nicolas previously developed high-tech optical products for major companies including Coherent, Ocular Sciences and Essilor. He has authored 12 patents, a PhD thesis on diffractive optics and dozens of scientific publications.

Xavier Levecq contributes boundless creativity in the development of Imagine Eyes’ products. Before the inception of Imagine Eyes, he also cofounded Imagine Optic together with Samuel Bucourt and designed new wavefront sensors that propelled their venture into an international success. Earlier, recruited while still at university by CILAS-EADS, Xavier developed high-tech optronic systems for « StarWars » military applications based on advanced space optics technologies. He has authored 30 patents.

Samuel Bucourt brings solid expertise in administration and finance, as well as salesforce organization and business development. In addition to his activities as CFO at Imagine Eyes, he works as CEO at Imagine Optic, a world-leading company in the area of optical wavefront sensors that he founded in association with Xavier Levecq in 1996.  Samuel also serves at Board Member and Treasurer at Photonics France, a nationwide association of photonics manufacturers.

Stéphane Sallmard brings an exceptional experience in management, paved with accomplishments in high-tech product marketing. As CEO of Optos Plc. in 2001, he drove the company’s sales from $1.5 million to $67 million in 5 years, and secured £50 million in funding when the company went public in 2006. Stéphane had previously demonstrated his skills in business development, marketing and finance at several innovative groups including IBM, Wang, Digital, Nixdorf, General Electric and Acuson Systems.

Jamal Labed co-founded EasyVista in 1988, a software editor for IT service management listed on Euronext. As EasyVista’s COO, he leads business operations and drives global strategy, while he also serves as board member for several tech start-ups. Prior to EasyVista, Jamal founded Sight International and Echo Soft Technologies, which he sold to Platinum Technology. France’s government has named him “Chevalier de la Légion d’Honneur” and Ambassador for the French Tech Diversity program.